Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a ...
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a …
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2–4 ...
Dec 19, 2024 · Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel targeted approach for treating IDHm glioma patients, yet their optimal use in clinical practice outside of …
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Jun 12, 2020 · Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is …
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a …
Feb 23, 2023 · The dual IDH1/IDH2 inhibitor vorasidenib exhibited better brain permeability and target engagement than ivosidenib in a pilot perioperative randomized clinical trial in patients …
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Jun 4, 2023 · Mellinghoff IK, Lu M, Wen PY, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med 2023;29:615-622.
Based on current evidence, ivosidenib for the treatment of IDH mutant glioma has Level 3 (low strength/quality) evidence supporting its use.10002,10003,10004,10005 Currently available …
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4 ...
Dec 19, 2024 · In this large cohort of IDHm glioma patients, ivosidenib was well tolerated. Our results support the use of IDHi therapy in patients with grade 2 or 3 astrocytoma or …
Ivosidenib off-label use for IDH mutant gliomas: The MD …
May 31, 2023 · Here, we describe our experience with off-label use of ivosidenib in IDH mutant gliomas. Methods: This is a retrospective case series study in a single cancer care institute.
The Role of Mutant IDH Inhibitors in the Treatment of Glioma
Sep 20, 2024 · Ivosidenib, an orally available mIDH1 inhibitor, was first investigated in a phase 1 study of 66 patients with recurrent/progressive pre-treated IDH1 -mutant glioma, grades 2–4 …
Treatment of IDH-mutant glioma in the INDIGO era - Nature
Jul 19, 2024 · Ivosidenib, a selective mIDH1 inhibitor, was tested in a phase I trial that enrolled IDH1-mutant glioma patients who had recurred or not responded to standard-of-care therapy 32.